Keytruda (pembrolizumab) has been approved for use in combination with chemoradiotherapy (CRT) for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to ...

Medscape Medical News, March 19, 2024 SGO 2024 QOL Not Harmed With Add-On Pembrolizumab in Cervical Cancer Adding pembrolizumab to concurrent chemoradiotherapy does not affect quality of life in ...

Pembrolizumab is under clinical development by Merck and ... more prior lines of therapy and for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or ...

Merck (NYSE:MRK) announced Saturday that its ant-PD-1 therapy Keytruda (pembrolizumab) reached the main goal in a Phase 3 ...

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared to chemoradiotherapy alone in patients with high-risk locally advanced ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

Medscape Medical News, September 20, 2024 ESMO 2024 Pembrolizumab Plus CCRT Improves Overall Survival Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab ...

Social support in patients with cervical cancer has the ability to provide patients with answers to some unknowns, and nurses can play a role in helping patients find this type of support. With ...

This study is looking at whether doctors can use a urine test to screen for cancer of the cervix. This trial is looking at pembrolizumab for cervical cancer that has spread into the surrounding tissue ...